Abrogation of High-Affinity IgE Receptor-Mediated Mast Cell Activation at the Effector Phase Prevents Contact Hypersensitivity to Oxazolone  by Kobayashi, Maiko et al.
Abrogation of High-Affinity IgE Receptor-Mediated
Mast Cell Activation at the Effector Phase Prevents
Contact Hypersensitivity to Oxazolone
Maiko Kobayashi1,2, Satoshi Nunomura1, Yasuhiro Gon1, Daisuke Endo1, Sachiko Kishiro1,
Makiko Fukunaga1, Yuko Kitahata1,2, Tadashi Terui2 and Chisei Ra1
Inflammatory mediators released from mast cells (MCs) through engagement of the high-affinity receptor for
IgE (FceRI) have pivotal roles in chemical allergen-induced contact hypersensitivity (CHS) reactions, which
suggests that the blockade of MC activation through FceRI stimulation may attenuate allergic contact dermatitis
(CD). To address this possibility, we employed the following two approaches: (i) modulation of FceRI-mediated
MC activation by introducing mutations in tyrosine residues of the FceRI b-chain immunoreceptor tyrosine-
based activation motif (ITAM) and (ii) blockade of FceRI-mediated MC activation employing a recombinant
soluble ecto-domain of the human FceRIa-chain (rsFceRIa). In this study, we show that optimal MC activation
through the FceRI b-chain ITAM has essential roles in the onset of CHS to oxazolone (Oxa), a well-characterized
chemical allergen. In addition, we demonstrate that administration of the rsFceRIa after sensitization successfully
prevents murine CHS to Oxa. In a chronic CD model elicited by multiple challenges with low-dose Oxa,
application of the rsFceRIa during the course of the challenges showed suppressive effects on CHS to Oxa. Taken
together, our data indicate that inhibition of FceRI-dependent MC activation can suppress allergic CD.
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INTRODUCTION
Langerhans cells (LCs) and T cells are widely believed to be
central effectors in the pathogenesis of type IV hypersensi-
tivity after challenge with contact allergens. Contact allergens
are chemically reactive haptens that can bind to soluble or
cell-associated proteins. After the first allergen sensitization,
LCs take allergens and migrate from the skin into the draining
lymph nodes where they prime naive T cells (Toews et al.,
1980; Jones et al., 1989). On re-challenge with the same
allergen, allergen-specific T cells in the lymph nodes are
activated and subsequently infiltrate the site of inflammation
where the allergen was repeatedly challenged (Girolomoni
et al., 2001; Saint-Mezard et al., 2004).
Recent studies employing mice deficient in mast cells
(MCs) suggest that inflammatory cytokines such as TNF-a
(tumor necrosis factor-a) and MIP-2 (macrophage-inflamma-
tory protein-2), which are released from MCs through the
engagement of high-affinity receptor for IgE (FceRI), have
crucial roles in LC migration and infiltration of leukocytes
including T cells (Biedermann et al., 2000; Nakae et al.,
2005; Suto et al., 2006). Therefore, MC-deficient strains of
mice show reduced contact hypersensitivity (CHS) to
haptens. However, local reconstitution of FceRI-positive
MCs into the sites of elicitation sufficiently restores the
defective CHS response in these mice (Biedermann et al.,
2000; Kakurai et al., 2006). These findings suggest that MC
activation through FceRI at inflammatory sites is one of
promising therapeutic targets for allergic contact dermatitis
(CD). As (i) FceRI b-chain (FcRb) regulates FceRI-signaling
and subsequent production of inflammatory cytokines in
MCs through three tyrosine residues (Y219/Y225/Y229)
within its immunoreceptor tyrosine-based activation motif
(ITAM) on FceRI cross-linking (Furumoto et al., 2004;
Nunomura et al., 2005; Xiao et al., 2005) and (ii) a
recombinant soluble ecto-domain of human FceRIa-chain
(rsFceRIa) prevents FceRI-mediated in vivo allergic reactions
by capturing free- and cell-bound IgE (Ra et al., 1993; Naito
et al., 1995, 1996; Ohtsuka et al., 1999), we employed FcRb-
ITAM mutant MCs and rsFceRIa to address this possibility in
this study.
In this study, we show that regulation of FceRI-dependent
MC activation through FcRb is critical for CHS to oxazolone
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(Oxa) and that prevention of FceRI-dependent MC activation
with rsFceRIa inhibits murine CHS responses induced by Oxa
challenge.
RESULTS
FceRI expression on MCs is indispensable for CHS to Oxa
The MC activation through FceRI is thought to contribute to
both the sensitization and the elicitation stages of CHS (Bryce
et al., 2004; Kakurai et al., 2006). Therefore, we examined
CHS response in FcRb/ mice, in which MCs are negative
for cell surface FceRI expression (Figure 1a). As shown in
Figure 1b, appropriate sensitization of mice with Oxa was
indispensable for specific CHS response to Oxa. Supplemen-
tary Figure S1 shows that FcRb/ and FcRbþ /þ mice had
comparable numbers of dermal MCs. As expected, however,
FcRb/ mice showed attenuated CHS to Oxa as compared
with FcRbþ /þ mice (Figure 1c and d).
FcRb-ITAM regulates the FceRI-dependent CHS to Oxa
Next, we examined whether FcRb-mediated MC activation at
the effector phase is critical for CHS to Oxa. For this purpose,
we prepared wild-type (abYYYg2) and mutated (abFFFg2)
FcRb-ITAM MCs (Figure 2a and b). Then, we performed
subcutaneous adoptive transfer of these cells into the ears of
MC-deficient W/Wv mice. Figure 2c shows that adoptive
transfer of abYYYg2 MCs, but not abFFFg2 MCs, successfully
restored the defective ear-swelling responses of W/Wv mice.
Consistent with this observation, more leukocytes, including
T cells and eosinophils, infiltrated the dermis in W/Wv mice
that received abYYYg2 MCs when compared with W/Wv mice
that received abFFFg2 MCs (Supplementary Figure S2).
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Figure 1. FcRb/ mice show attenuated contact hypersensitivity (CHS)
responses to oxazolone (Oxa) challenge. (a) Mast cells (MCs) from FcRb/
mice do not express FceRI on the cell surface. (b) FcRbþ /þ mice were
sensitized with 2% Oxa, 2% trinitrochlorobenzene (TNCB), or 2%
dinitrochlorobenzene (DNCB) on their shaved abdomen. TNCB and DNCB
were used as nonspecific contact sensitizers. These hapten-sensitized mice
were challenged with 1% Oxa or vehicle (ethanol) on the ear. After 18 hours,
ear thickness was evaluated with a dial micrometer. (c) FcRbþ /þ and FcRb/
mice were sensitized and challenged with Oxa as in b. Data shown are the
mean±SE. *Po0.05. (d) Hematoxylin and eosin (H&E) staining of the ear
tissues. (Bar¼ 70 mm).
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Figure 2. Mast cell (MC) activation through FcRb-ITAM positively regulates
contact hypersensitivity (CHS) reactions to oxazolone (Oxa). (a) Wild-type
FcRb (abYYYg2) and mutant FcRb-ITAM (abFFFg2), with three tyrosine residues
in the tyrosine-based activation motif (ITAM) replaced with phenylalanine.
(b) Comparable expression levels of cell surface FceRI and c-kit between
abYYYg2 and abFFFg2 cells. (c) abYYYg2 or abFFFg2 cells (1 106 per ml) were
subcutaneously transferred into the ears of W/Wv mice. As a control,
phosphate-buffered saline (PBS) was injected into the ears of W/Wv mice.
After the adoptive transfer, CHS was induced and evaluated as in Figure 1c.
Data shown are the mean±SE. *Po0.05.
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rsFceRIa prevents IgE binding to FceRI on MCs
Figures 1 and 2 suggest that prevention of FceRI-mediated
MC activation after the sensitization phase can attenuate CHS
to Oxa. To test this hypothesis, we prepared rsFceRIa with a
heterogeneous molecular weight (40–50 kDa) in accordance
with our and other previous reports (Blank et al., 1991; Yagi
et al., 1994; Gavin et al., 1995) (Supplementary Figure S3a).
As revealed by our previous study (Naito et al., 1996),
rsFceRIa completely prevented the binding of murine IgE
to the FceRI on bone marrow-derived MCs (BMMCs)
at approximately an equal molar ratio (Supplementary
Figure S3b).
Application of rsFceRIa after sensitization attenuates
CHS to Oxa
As shown in Figure 3a, culturing IgE-sensitized BMMCs
with rsFceRIa reduced the amounts of IgE bound to the FceRI
on their cell surface. Consequently, FceRI-mediated produc-
tion of inflammatory cytokines, TNF-a and IL-6, were
considerably decreased in BMMCs treated with rsFceRIa for
48 hours (Figure 3b). We therefore injected rsFceRIa
into mice 48 hours before Oxa challenge. Figure 3c shows
that intravenous administration of rsFceRIa significantly
decreased CHS response to Oxa. In contrast, administration
of rsFceRIa had no effects on induction of CD3 T cells
expressing CD69 in Oxa-sensitized splenocytes after stimu-
lation with Oxa-BSA (Figure 3d), suggesting that rsFceRIa
did not suppress sensitization process to generate hapten-
reactive T cells.
FcRb/ mice show attenuated CHS responses to multiple
Oxa challenges
Continuous exposure to contact allergen causes chronic CD.
We next explored the roles of FceRI-induced activation of
MCs in chronic CD mouse model induced by multiple
challenges with low-dose Oxa. As shown in Figure 4a, the
ears of FcRbþ /þ mice greatly swelled after the fifth Oxa
challenge (day 13). In contrast, FcRb/ mice showed a
reduced ear-swelling response throughout the Oxa chal-
lenges. Consistent with the above-mentioned findings, more
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Figure 3. Administration of rsFceRIa prevents the contact hypersensitivity (CHS) response to oxazolone (Oxa). (a) After bone marrow-derived MCs (BMMCs)
(5105 per ml) were cultured with 100 ngml1 of mouse IgE for 24 hours, rsFceRIa (1 mg) was added and the culture was continued for other 48 hours. After
washing, the cells were labeled with 0.1 mgml1 of FITC-conjugated anti-mouse IgE mAb. The amount of surface-bound IgE was expressed as mean fluorescence
intensity (MFI). (b) Reduction of FceRI-dependent production of TNF-a and IL-6 proteins in MCs treated with rsFceRIa. Data shown are the mean±SD of
triplicate samples. **Po0.01. (c) CHS was induced and evaluated as in Figure 1c. To inhibit FceRI-mediated responses, rsFceRIa (4 mg per animal) was
intravenously administered into mice at 3 days after sensitization. Data shown are the mean±SE. *Po0.05. (d) Mice were sensitized with Oxa as in Figure 1c.
rsFceRIa was administered into the mice as in Figure 3c. At 5 days after sensitization, splenocytes (2 105 per ml) were prepared and then stimulated with
10mgml1 of Oxa-BSA for 5 days. The percentage of net increase of CD3 T cells expressing CD69 was evaluated by flow cytometry. Data shown are the
mean±SD of triplicate samples.
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leukocytes infiltrated the dermis in FcRbþ /þ mice than in
FcRb/ mice after the fifth Oxa challenge (Figure 4b).
Supplementary Figure S4 shows that adoptive transfer of
wild-type BMMCs into the ears of FcRb/ mice sufficiently
restored their reduced ear-swelling responses, suggesting that
MC activation through FceRI is crucial for chronic CD to Oxa.
Administration of rsFceRIa successfully prevents CHS to
multiple Oxa challenges
We finally investigated whether single administration of
rsFceRIa during the course of hapten challenges prevents
cutaneous hypersensitivity (Figure 5a). As shown in Figure
5b, circulating IgE captured by rsFceRIa in sera was
detectable at day 15, 48 hours after the fifth Oxa challenge
(day 13), indicating that rsFceRIa is active at shortest until
6 days after the intravenous injection (day 9). Figure 5c shows
that administration of rsFceRIa after the third challenge had
no suppressive effect on CHS to the third challenge (day 9),
but significantly attenuated CHS responses to the fourth
(day 11) and fifth challenges (day 13). Histological analyses
show that the treatment with rsFceRIa considerably sup-
pressed infiltration of leukocytes into the dermis after the fifth
challenge (Figure 5d).
DISCUSSION
Allergic CHS is a representative of the delayed-type immune
response to contact allergens. Earlier studies showed that LCs
and T cells have critical roles in the sensitization and
elicitation stages of CHS, respectively. Recent studies suggest
that MCs also participate in the pathogenesis of CHS by
facilitating T-cell and LC activation (Shimada et al., 2003;
Bryce et al., 2004; Suto et al., 2006). These MCs require
FceRI-mediated signaling to act on T cells and LCs. We thus
conclude that FcRb/ mice showed severe defects in CHS
responses to Oxa due to abrogation of the FceRI expression
on the cell surface (Figure 1).
Nakashima et al. (2008) recently reported that inhibition
of T-cell memory at the sensitization phase, using the
immunosuppressive reagent FTY720, nearly abrogates CHS
responses, suggesting that the sensitization process is
biologically significant . We also found that the sensitization
process by a specific antigen is indispensable for specific
CHS responses (Figure 1b). However, individuals who
actually have allergic CD are already sensitized to some
contact allergens. For these patients, suppression of immune
responses after sensitization is essential to prevent the onset
of allergic CD. In this study, we employed two approaches to
investigate whether FceRI-dependent MC activation at the
effector phase could be a therapeutic target for allergic CD.
As shown in Figure 2c and Supplementary Figure S2,
adoptive transfer of abFFFg2 MCs failed to restore defects in
CHS responses of MC-deficient W/Wv mice. These data
clearly indicate that FcRb facilitates FceRI-induced MC
activation in vivo, namely activated MCs stimulated direct
infiltration of leukocytes. On the basis of these data, we
consider that abrogation of functional FcRb in MCs may be a
useful therapeutic strategy for the prevention of allergic CD.
Besides FcRb-ITAM transfectants, other approaches em-
ploying rsFceRIa emphasize the biological significance of
FceRI-dependent MC activation in the elicitation process of
CHS response. As shown in Supplementary Figure S3, pre-
incubation of murine IgE with rsFceRIa prevented its ability to
bind to the FceRI on MCs. In addition to this effect, culturing
IgE-sensitized MCs with rsFceRIa reduced amounts of cell-
bound IgE and suppressed FceRI-dependent production of
inflammatory cytokines, such as TNF-a and IL-6 (Figure 3a
and b). The ability of rsFceRIa to remove cell-bound IgE is
explained by a previous report, which showed that rsFceRIa
dissociates IgE from FceRI on the cell surface (Ra et al., 1993),
suggesting that rsFceRIa efficiently captures both circulating-
and cell-bound IgEs. We thereby conclude that rsFceRIa
suppressed ear-swelling response even when it was adminis-
tered after sensitization (Figure 3c). Like MCs, basophils
express FceRI at their cell surface but depletion of basophils
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Figure 4. FcRb/ mice show attenuated contact hypersensitivity (CHS)
responses to multiple oxazolone (Oxa) challenges. (a) FcRb/ and FcRbþ /þ
mice were sensitized with 5% Oxa. The sensitized mice were challenged with
0.1% Oxa every other day (challenges on days 5, 7, 9, 11, and 13 after
sensitization). Data shown are the mean±SE. **Po0.01; ***Po0.001.
(b) After the fifth challenge with 0.1% Oxa, tissue sections were prepared and
stained with Hematoxylin and eosin (H&E) (Bar¼ 70 mm).
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did not show any significant effects on the onset of CHS to
hapten (Obata et al., 2007). Therefore, we believe that the
inhibitory effects of rsFceRIa on CHS even after the
sensitization result from suppressive actions of rsFceRIa on
the IgE-FceRI-MC axis.
It is worth noting that rsFceRIa inhibits chronic CD elicited
by multiple Oxa challenges (Figure 5). A recent study using
IgE transgenic mice suggests that basophils, but not MCs, are
responsible for IgE-mediated passive chronic CD (Mukai
et al., 2005). Although we do not exclude the possibility that
rsFceRIa suppresses FceRI-dependent basophil activation
after multiple Oxa challenges, we speculate that FceRI-
dependent MC activation is the principal target of rsFceRIa
for chronic CD to Oxa under our experimental conditions
because adoptive transfer of FcRbþ /þ MCs obviously
restores defects in CHS response of FcRb/ mice to Oxa
(Supplementary Figure S4).
Our present results employing murine allergic CD model
indicate that prevention of FceRI-dependent MC activation is
a valuable therapeutic strategy for type IV hypersensitivity
reactions. However, it was reported that the mouse model
shows infiltration of neutrophils as effector cells, which is not
observed in the human system (Tuckermann et al., 2007).
Although we do not exclude the possibility that activation of
MCs through FceRI is relevant to particular murine CHS
response to chemical allergen, we hope that prevention of
IgE-FceRI-MC axis is effective also on human system.
MATERIALS AND METHODS
Reagents
Oxa, trinitrochlorobenzene, and dinitrochlorobenzene were
purchased from Sigma (St Louis, MO). Phycoerythrin-conjugated
anti-mouse CD117 mAb, FITC-conjugated anti-mouse CD3, and
phycoerythrin-conjugated anti-mouse CD69 mAbs were purchased
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Figure 5. Administration of rsFceRIa prevents contact hypersensitivity (CHS) response to multiple oxazolone (Oxa) challenges. (a) Chronic contact dermatitis
(CD) to Oxa as in Figure 4. After the third challenge (day 9), rsFceRIa (20 mg per animal) or phosphate-buffered saline (PBS) was immediately administered into
mice. (b) Sera were collected from the mice administrated with or without rsFceRIa after the fifth challenge with 0.1% Oxa. Total IgE was measured using a
specific ELISA kit. IgE captured with rsFceRIa was measured as described in Materials and Methods. Data shown are the mean±SE. (c) Ear thickness was
measured with a dial micrometer. Data shown are the mean±SE *Po0.05; **Po0.01. (d) After the fifth challenge, tissue sections were prepared and stained
with Hematoxylin and eosin (H&E) (Bar¼70 mm). Two representative results were displayed.
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from eBioscience (San Diego, CA). Rat anti-mouse IgE (IgE-3), biotin-
or FITC-conjugated anti-mouse IgE (R35-72) mAbs were purchased
from BD Biosciences (San Diego, CA). BSA conjugated with Oxa
was prepared in our laboratory. Mouse anti-human FceRIa mAbs
(CRA1 and CRA2) were prepared from ascitic fluid in our laboratory.
Preparation of rsFceRIa
rsFceRIa was prepared in our laboratory as previously described
(Naito et al., 1996). Briefly, culture supernatants from Chinese
Hamster Ovary cells secreting rsFceRIa were collected. The super-
natant was concentrated with the Centricon-Plus 70 (Millipore,
Bedford, MA) concentrator. The rsFceRIa protein was purified from
the supernatant by employing an affinity column (HiTrap NHS-
activated HP column; GE Healthcare Bio-sciences, Little Chalfont,
UK) coupled with 5mg of anti-human FceRIa mAb (CRA2).
Mice
FcRb/ mice (C57BL6 129sv mixed background) (Hiraoka et al.,
1999) were backcrossed for seven generations onto the C57BL/6
background. C57BL/6J mice were purchased from Charles River
Laboratories Japan (Kanagawa, Japan) as littermate controls for FcRb/
 mice. W/Wv mice were purchased from Japan SLC (Shizuoka, Japan).
After the approval of a committee of animal welfare at Nihon University,
all experiments were performed in accordance with the guidelines for
the care and use of laboratory animals of Nihon University.
Flow cytometry
For evaluation of FceRI expression at the cell surface, MCs (2 105)
were incubated with 1mgml1 of anti-TNP IgE (IgE-3) at 4 1C for
30minutes in 0.1ml phosphate-buffered saline containing 0.1%
sodium azide and then washed twice with the same buffer. The cells
were further labeled with 0.1 mgml1 of anti-mouse IgE mAb
conjugated with FITC at 4 1C for 30minutes. The labeled cells were
analyzed using a FACSCalibur cytometer (BD Biosciences).
Sensitization and elicitation of CHS
Mice were sensitized with 100 ml of 2% Oxa on their shaved
abdomens. From day 5, the Oxa-sensitized mice were challenged
with 10ml of 1% Oxa or vehicle (ethanol) on the ear. Chronic CD
was induced by sensitization with 5% Oxa and multiple challenges
with 0.1% Oxa as described previously (Man et al., 2008). Oxa
challenges were performed on days 5, 7, 9, 11, and 13 after
sensitization. Ear thickness was measured with a dial micrometer
(Mitutoyo, Tokyo, Japan). The net increase in ear thickness was
calculated as follows: (thickness of ears after Oxa applicationthick-
ness of ears before Oxa application)(thickness of ears after vehicle
applicationthickness of ears before vehicle application).
Cell culture
Cultures of BMMCs were prepared from the femurs of 4- to 8-week-
old mice as previously described (Nunomura et al., 2008). For
retroviral transfection, bone marrow cells derived from FcRb/
mice were cultured in the presence of 100 ngml1 recombinant SCF
(PeproTech, Rocky Hill, NJ) for another 7 days.
Retroviral transfection
Retroviral gene transduction into FcRb/ MCs was performed as
previously described (Nunomura et al., 2005). Briefly, pMX-puro
plasmids harboring wild-type (abYYYg2) or mutated (abFFFg2) FcRb
cDNAs were transfected into PLAT-E (kindly gifted by Dr Toshio
Kitamura at Tokyo University, Japan) to generate recombinant
retroviruses. Bone marrow cells were infected with the retroviruses
for 48 hours and then the gene-transduced cells were selected with
1.2 mgml1 puromycin for 7 days. Viable cells were further
expanded for several weeks, and puromycin-resistant MCs were
used for subsequent experiments. The cells (1 106) were sub-
cutaneously transferred into the ears of mice as previously described
(Watanabe et al., 1999).
Measurement of TNF-a and IL-6 production
IgE-sensitized MCs (2 105) were stimulated with 10 ngml1 of
TNP-BSA for 8 hours in 0.2ml of RPMI-1640 medium supplemented
with 2% (v/v) fetal bovine serum. TNF-a and IL-6 production
was analyzed with specific ELISA kits (BioSource International,
Camarillo, CA).
Measurement of IgE Abs
Total mouse IgE Ab in serum was analyzed by a specific ELISA kit
(Yamasa Corporation, Tokyo, Japan). The levels of IgE captured with
rsFceRIa in sera were measured using a sandwich ELISA. Briefly, an
ELISA plate was coated with anti-human FceRIa mAb (CRA1)
(10 mgml1) and then washed thrice with Tris-buffered saline (TBS)
containing 0.05% Tween-20 (TBS-T). Diluted serum samples were
added to the wells and incubated for 2 hours. After washing with
TBS-T, biotinylated anti-mouse IgE was added to each well and
incubated for 1 hour. After washing with TBS-T, the wells were
incubated with avidin-conjugated with HRP (BD Bioscience) for
30minutes and then washed with TBS-T. The reaction was
developed with substrate chromogen for 30minutes and stopped
by the addition of an equal volume of 2M H2SO4. Optical
absorbance at wavelength of 450 nm was measured. The reaction
product of rsFceRIa and mouse IgE (IgE-3) was used as standard.
Statistical analysis
Statistical analysis was performed using the unpaired Student’s t-test.
Probability values of o0.05 represented statistically significant
differences.
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